CPC C07K 16/3007 (2013.01) [A61K 39/39558 (2013.01); C12N 15/62 (2013.01); G01N 33/57492 (2013.01); A61K 35/17 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70503 (2013.01)] | 18 Claims |
1. A pharmaceutical composition comprising a humanized monoclonal antibody (mAb) or a fragment thereof, which specifically recognizes human Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), wherein the mAb or fragment thereof comprises:
(i) a heavy-chain variable region amino-acid sequence comprising the three CDR sequences set forth in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and the four framework sequences set forth in: (a) SEQ ID NO:7 or SEQ ID NO:15; (b) SEQ ID NO:16 or SEQ ID NO:17; (c) SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 or SEQ ID NO:22; and (d) SEQ ID NO:10 or SEQ ID NO:23;
and
(ii) a light-chain variable region amino-acid sequence comprising the three CDR sequences set forth in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, and the four framework sequences set forth in: (a) SEQ ID NO:11; (b) SEQ ID NO:24; (c) SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; and (d) SEQ ID NO:14;
and a pharmaceutically acceptable carrier, diluent or excipient.
|